Unicycive Therapeutics Reports Q3 2026 Results, $59 Million in Cash and Securities
Unicycive Therapeutics reported a Q3 2026 net loss of $7.0 million, or $0.25 per share, with $59 million in cash. The FDA accepted its OLC NDA resubmission, setting a March 25, 2027 PDUFA date. The company expects its cash runway to extend beyond 2027, including potential OLC launch costs. Research and development expenses decreased to $2.2 million from $3.0 million a year earlier, while general and administrative expenses increased to $6.6 million from $4.4 million.
How this was made

The 30-second read
Why it matters
The FDA’s acceptance and the March 25, 2027 PDUFA target date create a clearer regulatory timeline, while the cash runway extension beyond 2027 reduces financing risk. However, vendor-related manufacturing readiness and potential pre-approval inspection remain key execution risks.
Market read
Traders get a concrete FDA milestone (acceptance plus PDUFA date) and updated liquidity/runway, which can shift probability-weighted valuation for a small-cap biotech.
What to watch
CMS TDAPA eligibility is contingent on FDA approval and CMS confirmation, so reimbursement upside may be delayed or reduced if eligibility criteria are not met.
Background
Unicycive resubmitted its oxylanthanum carbonate (OLC) NDA after a June 2026 Complete Response Letter citing deficiencies at the original drug product vendor, without new clinical efficacy or safety concerns.
Ticker impact
Unicycive Therapeutics reports Q3 2026 results and says the FDA accepted its resubmitted OLC NDA with a March 25, 2027 PDUFA action date.
Likely upward bias as traders price improved regulatory path and a clear catalyst date, offset by ongoing vendor-inspection uncertainty.
The article provides a fresh regulatory milestone (FDA acceptance plus PDUFA target date) and cash runway details, both of which can affect valuation and probability-weighted outcomes.
Market effects
Reinforces that dialysis-phosphate binder reimbursement and TDAPA eligibility can materially affect biotech commercial economics.
None specific beyond US FDA/CMS policy relevance.
Limited, primarily US regulatory and reimbursement-driven.
Counterpoint
The FDA acceptance does not guarantee approval, and the article flags uncertainty around whether a pre-approval inspection will occur.
Key entities
- companyUnicycive Therapeutics
Reports Q3 2026 financials and provides an FDA timeline for its resubmitted OLC NDA.
- drug_candidateOxylanthanum carbonate (OLC)
Dialysis phosphate binder whose NDA resubmission was accepted by the FDA with a March 25, 2027 PDUFA target date.
- regulatorFDA
Accepted the OLC NDA resubmission and set a PDUFA target action date.
- regulatorCMS
Finalized dialysis base rate addition effective January 1, 2027 and a hyperphosphatemia clinical quality measure beginning payment year 2029.

